IR-guided Ablation (IRGA) Combined With Stereotactic Ablative Radiation (SABR) for Large Lung Tumors

• ClinicalTrials.gov Identifier: NCT01746810
• Recruitment Status: Terminated
• First Posted: December 11, 2012
• Last Update Posted: November 17, 2017
• Sponsor: New Mexico Cancer Care Alliance
• Information provided by (Responsible Party): New Mexico Cancer Care Alliance

Study Description

Brief Summary:

This phase I trial studies the side effects and best dose of stereotactic body radiation therapy when given together with ablation therapy in treating patients with non-small cell lung cancer or lung metastases. Ablation therapy, such as radiofrequency ablation uses a high-frequency, electric current to kill tumor cells. Ablation therapy, such as microwave ablation kills tumor cells by heating them to several degrees above normal body temperature. Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Giving ablation therapy together with stereotactic body radiation therapy may kill more tumor cells.

Condition or disease	Intervention/treatment	Phase
Recurrent Non-small Cell Lung Cancer	Radiation: Stereotactic body RT and IRGA	Phase 1

Detailed Description:

This is a dose-escalation study of stereotactic body radiation therapy.

Patients undergo stereotactic body radiation therapy once daily (QD) for a total of 5 fractions and then undergo IRGA (either radiofrequency ablation or microwave ablation) 1 week later.

After completion of study treatment, patients are followed up at 4 weeks, every 3 months for 1 year, every 4 months for 1 year, every 6 months for 3 years, and then annually thereafter.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 1 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: IR-guided Ablation (IRGA) Combined With Stereotactic Ablative Radiation (SABR) for Lung Tumors Larger Than 3 cm: Phase I Dose Escalation and Pilot Study With Companion Biomarker Analysis
• Actual Study Start Date: July 2012
• Actual Primary Completion Date: October 2015
• Actual Study Completion Date: October 13, 2015

Arms and Interventions

Arm	Intervention/treatment
Experimental: Stereotactic Body RT and IRGA; Patients undergo stereotactic body radiation therapy QD for a total of 5 fractions and then undergo IRGA (either radiofrequency ablation or microwave ablation) 1 week later.	Radiation: Stereotactic body RT and IRGA; SABR Treatment with Dose escalation: Group 1: 40 Gy/5 fractions Group 2: 45 Gy/5 fractions Group 3: 50 Gy/5 fractions then IRGA procedure 1 week later with repeat lung biopsies, serum studies; Other Names: Radiofrequency ablation; Microwave ablation

Outcome Measures

Primary Outcome Measures :

1. Maximum Tolerated Dose (MTD) [ Time Frame: 30 to 90 days ]
   The MTD will be defined as the highest dose level where less than or equal to 33% patients incurred a dose-limiting toxicity (DLT). A DLT will be defined as an acute (within 30 days) or subacute (31-90 days) irreversible grade 3 or any grade 4-5 toxicity (using National Cancer Institute [NCI]-Common Toxicity Criteria [CTC] version 4.0 criteria) that is possibly, probably, and definitely attributed to the therapy.

Secondary Outcome Measures :

1. Survival [ Time Frame: Up to 6 years ]
   Rates of local control, disease-free survival, and overall survival
2. Biomarker testing [ Time Frame: 2 weeks ]
   Size of tissue samples sufficient for DNA analyses
3. Pathological Response [ Time Frame: Up to 6 years ]
   Pathological response, changes in protein expression, and biomarker correlations with clinical outcome
4. Quality of Life [ Time Frame: Up to 6 years ]
   Quality of life (European Organization for the Research and Treatment of Cancer [EORTC])

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Pathological (histologically or cytologically) diagnosis of non-small cell lung cancer (NSCLC); or if lung tumor is considered to be metastases (even from primary NSCLC), then clinical diagnosis is sufficient
• For NSCLC: Staging workup at initial diagnosis demonstrates T2-T4N0M0, or T2-T4,N1-3,M1; node-positive patients will be allowed on study only if they have M1 disease; clinical diagnosis of M1 disease is sufficient
• Patient is deemed (a) to be medically inoperable after evaluation by thoracic surgeon based on, but not limited to the following: baseline forced expiratory volume in one second (FEV1) < 40% predicted, post-operative FEV1 < 30% predicted, severely reduced diffusion capacity, baseline hypoxemia/hypercapnia, coronary artery disease, end-organ damage, or (b): patient has refused surgery after thoracic surgery consultation
• Eastern Cooperative Oncology Group (ECOG) performance status 0-2
• NSCLC only: pleural effusion, if present, will undergo routine assessment for malignancy; inability to obtain fluid or non-diagnostic cytology will not preclude eligibility
• Negative serum or urine pregnancy test within 4 weeks prior to registration in women with childbearing potential
• Able to provide written, informed consent
• Minimum of 4 weeks from last dose of chemotherapy to start of treatment

Exclusion Criteria:

• For NSCLC only: prior invasive malignancy (except non-melanoma skin cancer) unless disease-free for a minimum of 2 years, including previous history of lung cancer
• Prior radiation to the region of current cancer that would result in > 50% overlap of the old treatment field on the new treatment area based on radiation oncologist evaluation
• International normalization ratio (INR) of > 1.5
• Platelets of < 50,000 /uL
• Inability to meet maximum point dose constraints

Contacts and Locations

Locations

United States, New Mexico

University of New Mexico Cancer Center

Albuquerque, New Mexico, United States, 87131

Sponsors and Collaborators

New Mexico Cancer Care Alliance

Investigators

• Principal Investigator: Thomas Schroeder, MD; UNM Cancer Center

More Information

Additional Information:

UNM Cancer Center 

New Mexico Cancer Care Alliance 

• Responsible Party: New Mexico Cancer Care Alliance
• ClinicalTrials.gov Identifier: NCT01746810
• Other Study ID Numbers: INST 1206
• First Posted: December 11, 2012
• Last Update Posted: November 17, 2017
• Last Verified: November 2017

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

Keywords provided by New Mexico Cancer Care Alliance:

Metastatic; Lung Cancer; NSCLC

Additional relevant MeSH terms:

Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases